Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision making.
In the present study we investigated the predictive value of standard serum markers as well as clinical markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in an unselected prospective patient population treated with sunitinib for mRCC. Forty-six patients were enrolled in a prospective single-arm study of predictive markers for sunitinib response. Response rates according to RECIST 1.1 were used as primary end-point. Secondary objectives were to evaluate prognostic value of the candidate markers with regard to progression free survival (PFS) and overall survival (OS). In addition, toxicity rates and quality of life was recorded.
Median PFS and OS was 9.1 months and 15.0 months, respectively. Of 38 patients evaluable for response, 1 patient had complete response (CR), 7 had partial response (PR), 18 had stable disease (SD) and 12 had progressive disease (PD). Normal CRP at baseline was significantly associated with objective response (CR + PR) (p = 0.01). Normal CRP was also significantly associated with improved PFS and OS (Log rank, p = 0.05 and <0.01, respectively). Early hypertension, NLR and IMDC risk score were not significantly associated with response rates or survival.
Baseline CRP was a significant predictive factor of sunitinib response and a prognostic factor of survival. Baseline CRP might be a useful biomarker in the treatment planning of mRCC. Due to the relatively small sample size, our results need to be confirmed in larger studies.
BMC urology. 2017 Aug 31*** epublish ***
Martin Pilskog, Christian Beisland, Lars A Akslen, Leif Bostad, Åse Haug, Daniel Heinrich, Karin M Hjelle, Oddbjørn Straume
Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway., Department of Urology, Haukeland University Hospital, 5021, Bergen, Norway., Department of Pathology, Haukeland University Hospital, 5021, Bergen, Norway., Department of Oncology, Haukeland University Hospital, 5021, Bergen, Norway., Department of Oncology, Akershus University Hospital, 1478, Lørenskog, Norway., Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway. .